With an aging population, Alzheimer’s is the only rising case of death; prevention of dementia due to Alzheimer’s disease has to be the way forward. This requires greater understanding of the cause of the disease, the biomarkers that enable early, accurate diagnosis and access to new generation treatments designed to slow down or, ideally, stop progression of early symptoms. Recent results for new treatments may be, at last, a cause for cautious optimism.
Dr MacSweeney is CEO and Medical Director of award winning mind and brain clinic Re:Cognition Health. Dr MacSweeney co- founded Re:Cognition Health in 2011 to provide a specialist service in the neurological assessment and imaging of cognitive impairment, neurovascular diseases and traumatic brain injury, including the provision medico-legal expert opinion. The Re:Cognition Health Clinics in London, Birmingham, Essex, Surrey and Plymouth and Washington DC are also major centres for international trials of disease-modifying and new symptomatic drugs for Alzheimer’s disease and other neurological conditions. Re:Cognition’s expertise has been recognised with numerous prestigious accolades including EY Entrepreneur of the Year Winner- Societal Impact 2019 (London and South England) Growing Business Awards- Positive Impact Winner 2019, Health Investor Awards 2019 finalist, CEO Today Magazine - Healthcare Awards Winner 2019, Doctify – Excellent Patient Experience 2019, LaingBuisson Healthcare Awards for Excellence (finalist or winner; 2012, 2013, 2015, 2018, 2019) and KPMG Entrepreneur of the Year Winner 2016.